Studies on Blood Biomarker for Traumatic Brain Injury
Over the last few months, new technology brought to the NYU Langone Medical Center will potentially help researchers advance blood biomarker capabilities. If studies are properly recorded, the researchers will be able to observe changes in low concentration of proteins after sustaining a neurological injury. These tests will be conducted with the help of single molecule array technology that has been developed by Quanterix, in addition to the fully automated HD-1 analyzer. In conjunction, the two tools offer never before seen improvement in the analysis of sensitivity proteins for the detection of blood-based biomarkers. In narrower, scientific terms, these technological implementations allow for better measurements of low concentration proteins like tau, a protein that is discharged from brain cells after brain injuries. Hopefully, researchers will be able create simpler and more objective blood biomarkers for the effective treatment of traumatic brain injury.
“This diagnostic advancement provides us with a more precise ruler for measuring the effectiveness of diagnosis, treatment and progression of TBI,” says Mony J. de Leon, EdD, director of the Center for Brain Health at NYU Langone, professor of psychiatry and an investigator with NYU’s Steven and Alexandra Cohen Veterans Center. “We know that increased tau proteins in the cerebrospinal fluid are a marker for TBI. Having more immediate and consistent access to tau measurements from the blood or saliva will allow us to more accurately determine if a brain injury has, indeed, occurred, and how well a patient is responding to treatment.”
At this point, the technology researchers use to detect specific proteins and biomarkers in the blood are limited. Observation of the cerebrospinal fluid (CSF) has been the normal approach to measure proteins, but the process requires invasive methods. Also, this form of evaluation is not always available because of certain injuries, and, in truth, it is impossible to record progression. Because the issues pertaining to these procedures, a large number of patients who appear to have made a recovery during x-ray tests can still suffer from undetectable damages. It is imperative for doctors to know the extensive damages to properly treat the patient.
“The Quanterix Simoa will accelerate the discovery of new biomarkers to identify TBI and the development of new treatments, including targeted medications and other therapies,” says Charles L. Marmar, MD, the Lucius Littauer professor and chairman of Psychiatry at NYU Langone and executive director of the Cohen Veterans Center. “It is truly a breakthrough for advancing detection and treatment of brain injuries.”
Source: medicalxpress.com, NYU School of Medicine